215 related articles for article (PubMed ID: 18845988)
1. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study.
Rathore R; Safran H; Soares G; Dubel G; McNulty B; Ahn S; Iannitti D; Kennedy T
Am J Clin Oncol; 2010 Feb; 33(1):43-6. PubMed ID: 19687731
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
[TBL] [Abstract][Full Text] [Related]
6. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Raguse JD; Gath HJ; Oettle H; Bier J
Oral Oncol; 2006 Jul; 42(6):614-8. PubMed ID: 16488656
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY; Fisher GA; So S; Tang C; Levitt L
Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Lim JY; Jeung HC; Mun HS; Lee DK; Paik YH; Lee SJ; Yoon DS; Cho JY
Anticancer Drugs; 2008 Jul; 19(6):631-5. PubMed ID: 18525323
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
Nagata H; Hatano E; Asechi H; Narita M; Yanagida A; Yasuchika K; Ikai I; Uemoto S
Gan To Kagaku Ryoho; 2007 Feb; 34(2):233-5. PubMed ID: 17301534
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of oxaliplatin in urothelial cancer.
Winquist E; Vokes E; Moore MJ; Schumm LP; Hoving K; Stadler WM
Urol Oncol; 2005; 23(3):150-4. PubMed ID: 15907713
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
Oh SY; Lee GW; Kim HG; Kim TH; Kim HJ; Kang JH
Chemotherapy; 2008; 54(6):479-84. PubMed ID: 18832821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
